101
|
Miller H, Ike C, Parma J, Masand RP, Mach CM, Anderson ML. Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. Sarcoma 2016; 2016:7018106. [PMID: 27721667 PMCID: PMC5046025 DOI: 10.1155/2016/7018106] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Revised: 08/05/2016] [Accepted: 08/18/2016] [Indexed: 12/20/2022] Open
Abstract
Uterine leiomyosarcoma (uLMS) is an aggressive malignancy characterized by its early metastasis, high rates of recurrence, and poor prognosis. Multiple obstacles complicate the clinical management of uLMS. These include the fact that most uLMS are typically identified only after a woman has undergone hysterectomy or myomectomy, the limited efficacy of adjuvant therapy for early stage disease, and the poor response of metastatic disease to current treatments. Here, we discuss recent insights into the molecular basis of uLMS and discuss emerging options for its clinical management. Particular attention is given to the biologic basis of these strategies with the goal of understanding the rationale motivating their use.
Collapse
Affiliation(s)
- Heather Miller
- Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Chiemeka Ike
- College of Pharmacy, University of Houston, Houston, TX 77030, USA
| | - Jennifer Parma
- College of Pharmacy, University of Houston, Houston, TX 77030, USA
| | - Ramya P. Masand
- Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Claire M. Mach
- Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
- College of Pharmacy, University of Houston, Houston, TX 77030, USA
| | - Matthew L. Anderson
- Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
- Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030, USA
- Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| |
Collapse
|
102
|
Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS, Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, Yoo KH, Sung KW, Koo HH, Kang HJ, Park KD, Shin HY, Koh KN, Im HJ, Seo JJ, Lim YJ, Baek HJ, Kook H. Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy. Pediatr Blood Cancer 2016; 63:1552-6. [PMID: 27197055 DOI: 10.1002/pbc.26058] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 04/19/2016] [Indexed: 11/06/2022]
Abstract
BACKGROUND Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. METHODS Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m(2) on days 1 and 8) and DOC (100 mg/m(2) on day 8), were retrospectively reviewed. RESULTS GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1-10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m(2) GEM than in patients receiving 675 mg/m(2) (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). CONCLUSIONS Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.
Collapse
Affiliation(s)
- Jun Ah Lee
- Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Republic of Korea
| | - Dae-Geun Jeon
- Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
| | - Wan Hyeong Cho
- Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
| | - Won Seok Song
- Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
| | - Hoi Soo Yoon
- Department of Pediatrics, Kyung Hee University School of Medicine, Seoul, Republic of Korea
| | - Hyeon Jin Park
- Center for Pediatric Oncology, National Cancer Center, Goyang, Seoul, Republic of Korea
| | - Byung Kiu Park
- Center for Pediatric Oncology, National Cancer Center, Goyang, Seoul, Republic of Korea
| | - Hyoung Soo Choi
- Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Seoul, Republic of Korea
| | - Hyo Seop Ahn
- Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Seoul, Republic of Korea
| | - Ji Won Lee
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Keon Hee Yoo
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Ki Woong Sung
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Hong Hoe Koo
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Hyoung Jin Kang
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Kyung Duk Park
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Hee Young Shin
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Kyung-Nam Koh
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Ho Joon Im
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Jong Jin Seo
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Yeon Jung Lim
- Department of Pediatrics, Chungnam National University College of Medicine, Daejon, Republic of Korea
| | - Hee Jo Baek
- Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Hoon Kook
- Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea
| |
Collapse
|
103
|
Desar IME, Constantinidou A, Kaal SEJ, Jones RL, van der Graaf WTA. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Manag Res 2016; 8:95-104. [PMID: 27574465 PMCID: PMC4993282 DOI: 10.2147/cmar.s86746] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.
Collapse
Affiliation(s)
- Ingrid M E Desar
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | | | - Suzanne E J Kaal
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Robin L Jones
- The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK
| | - Winette T A van der Graaf
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
- The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
104
|
Wen KC, Horng HC, Wang PH, Chen YJ, Yen MS, Ng HT. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwan J Obstet Gynecol 2016; 55:463-471. [PMID: 27590365 DOI: 10.1016/j.tjog.2016.04.033] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2016] [Indexed: 12/21/2022] Open
Abstract
Uterine sarcomas account for 3-7% of all uterine cancers. Because of their rarity, unknown etiology, and highly divergent genetic aberration, there is a lack of consensus on risk factors for occurrence and predictive poor outcomes as well as optimal therapeutic choices. Tumor types according to the World Health Organization classification include leiomyosarcoma, endometrial stroma sarcoma, and undifferentiated sarcoma. Staging is done using the 2014 Federation International Gynecology and Obstetrics and 2010 American Joint Committee on Cancer tumor, lymph node, and metastases systems. Tumor grade can be classified based on the French Federation of Cancer Centers Sarcoma Group system or the Broder's system that incorporates tumor differentiation, mitotic count, and tumor necrosis. This review is a series of articles discussing uterine sarcoma, and this is Part I, which focuses on one of the subtypes of uterine sarcomas-uterine leiomyosarcoma. The clinical characteristics, diagnosis, outcome, and recent advances are summarized in this article.
Collapse
Affiliation(s)
- Kuo-Chang Wen
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan
| | - Huann-Cheng Horng
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan
| | - Peng-Hui Wang
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
| | - Yi-Jen Chen
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan
| | - Ming-Shyen Yen
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan
| | - Heung-Tat Ng
- Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Foundation of Female Cancer, Taipei, Taiwan
| |
Collapse
|
105
|
Affiliation(s)
- Nicholas S Reed
- Beatson Oncology Centre; Gartnavel General Hospital; Glasgow G12 0YN Scotland UK
| | - Azmat H Sadozye
- Beatson Oncology Centre; Gartnavel General Hospital; Glasgow G12 0YN Scotland UK
| |
Collapse
|
106
|
NAGAMATA SATOSHI, EBINA YASUHIKO, YAMANO YUMIKA, MIYAMOTO TAKEO, NISHIJIMA MITSUHIRO, YAMADA HIDETO. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib. THE KOBE JOURNAL OF MEDICAL SCIENCES 2016; 62:E45-E48. [PMID: 27578036 PMCID: PMC5425135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 03/18/2016] [Indexed: 06/06/2023]
Abstract
Uterine leiomyosarcoma (ULMS) is an aggressive tumor associated with high rates of progression, recurrence, and mortality. Pazopanib is the only approved molecular targeted drug for advanced soft tissue sarcoma, and it has been proven to prolong progression-free survival relative to placebo. We herein report a case of ULMS with multiple lung metastases treated with pazopanib, which led to sustained disease control for 44 weeks. A 53-year-old woman was referred to our hospital due to massive uterine bleeding from a uterine corpus tumor mass. Total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed as emergency surgery. The final histopathological diagnosis was uterine leiomyosarcoma, and computed tomography revealed multiple lung metastases. After chemotherapy with 17 cycles of gemcitabine and docetaxel and two cycles of doxorubicin, the lung metastases had increased in size and new lesions had appeared. Pazopanib administration at 800 mg/day was started as third-line therapy. Ten weeks later, the dose of pazopanib was reduced to 600 mg/day because of hepatic impairment and hypertension. However, lung metastases of ULMS were stabilized by pazopanib administration for about 44 weeks without a decline in the patient's quality of life. After 44 weeks of therapy, pazopanib administration was discontinued because of progressive disease and worsening of the patient's respiratory status. Pazopanib is an oral multityrosine kinase inhibitor of vascular endothelial growth factor receptor-1, -2, and -3; platelet-derived growth factor-α and -β; and c-Kit receptor. The role of pazopanib may be clinically significant in the treatment of advanced ULMS.
Collapse
Affiliation(s)
- SATOSHI NAGAMATA
- Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
| | - YASUHIKO EBINA
- Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
| | - YUMIKA YAMANO
- Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
| | - TAKEO MIYAMOTO
- Department of Obstetrics and Gynecology, Hyogo Prefectural Awaji Medical Center, 1-1-137 Shioya, Sumoto, Hyogo 656-0021, Japan
| | - MITSUHIRO NISHIJIMA
- Department of Obstetrics and Gynecology, Hyogo Prefectural Awaji Medical Center, 1-1-137 Shioya, Sumoto, Hyogo 656-0021, Japan
| | - HIDETO YAMADA
- Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
| |
Collapse
|
107
|
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. Gynecol Oncol 2016; 142:95-101. [DOI: 10.1016/j.ygyno.2016.05.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 05/10/2016] [Accepted: 05/15/2016] [Indexed: 01/12/2023]
|
108
|
A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. AJR Am J Roentgenol 2016; 207:4-14. [DOI: 10.2214/ajr.15.15480] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
109
|
Seddon B. First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes? Curr Opin Oncol 2016; 28:323-30. [DOI: 10.1097/cco.0000000000000301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
110
|
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. J Clin Oncol 2016; 34:2294-302. [PMID: 27185843 DOI: 10.1200/jco.2015.65.3329] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Doxorubicin and trabectedin are considered active drugs in soft tissue sarcoma (STS). The combination of both drugs was hypothesized to be advantageous and safe on the basis of preclinical evidence and a previous phase I trial, respectively. The aim of this study was to compare the clinical outcome of trabectedin plus doxorubicin with doxorubicin as first-line treatment of advanced STS patients. PATIENTS AND METHODS In this open-label randomized phase II trial, the main end point was progression-free survival (PFS). Trabectedin 1.1 mg/m(2) in a 3-hour infusion plus doxorubicin 60 mg/m(2) as the experimental arm and doxorubicin 75 mg/m(2) as the control arm were administered for up to six cycles. Translational research was planned to correlate the expression of apoptotic and DNA repair genes with clinical outcome. RESULTS In 115 randomly assigned patients, the median PFS was 5.5 months in the control arm and 5.7 months in the experimental arm (hazard ratio, 1.16; 95% CI, 0.79 to 1.71; P = .45) in the intent-to-treat analysis. The trial was stopped for futility after the interim analysis, because the results in the experimental arm showed the risk reduction for the main end point to be < 9.64%. The proportion of patients with grade 3 or 4 thrombocytopenia, asthenia, and liver toxicity was significantly higher in the experimental arm. FAS and p53 were shown to be prognostic factors for PFS (7.0 months if FAS+ and p53-; 3.4 months if FAS+/p53+ or FAS-/p53-; and 0.7 months if FAS- and p53+; P < .001) and for overall survival. CONCLUSION Trabectedin plus doxorubicin did not show superiority over doxorubicin alone as first-line treatment of advanced STS. The prognostic role of apoptotic key genes, FAS and p53, was shown to be robust enough to continue this research line.
Collapse
Affiliation(s)
- Javier Martin-Broto
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain.
| | - Antonio López Pousa
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Ramón de Las Peñas
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Xavier García Del Muro
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Antonio Gutierrez
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Javier Martinez-Trufero
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Josefina Cruz
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Rosa Alvarez
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Ricardo Cubedo
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Andrés Redondo
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Joan Maurel
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Juan A Carrasco
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - José A López-Martin
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Ángeles Sala
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - José Andrés Meana
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Rafael Ramos
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Jordi Martinez-Serra
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - José A Lopez-Guerrero
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Isabel Sevilla
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Carmen Balaña
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Ángeles Vaz
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Ana De Juan
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Regina Alemany
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| | - Andrés Poveda
- Javier Martin-Broto, Virgen del Rocio Hospital and Biomedicine Institute, Sevilla; Antonio López Pousa, Sant Pau Hospital; Xavier García del Muro, Institut Català d'Oncologia; and Joan Maurel, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona; Ramón de las Peñas, Provincial Hospital, Castellón; Antonio Gutierrez, Rafael Ramos, and Jordi Martinez-Serra, Son Espases Hospital; and Regina Alemany, Balearic Islands University, Palma de Mallorca; Javier Martinez-Trufero, Miguel Servet Hospital, Zaragoza; Josefina Cruz, University Hospital Canarias, Tenerife; Rosa Alvarez, Gregorio Marañón Hospital; Ricardo Cubedo, Puerta de Hierro Hospital; Andrés Redondo, La Paz University Hospital; José A. López-Martin, 12 de Octubre Hospital; and Ángeles Vaz, Ramón y Cajal Hospital, Madrid; Juan A. Carrasco, Xeral Cies Hospital, Vigo; Ángeles Sala and Ana De Juan, Basurto Hospital, Bilbao; José Andrés Meana, University General Hospital, Alicante; José A. Lopez-Guerrero and Andrés Poveda, Valencian Oncologic Institute, Valencia; Isabel Sevilla, Virgen de la Victoria Hospital, Málaga; and Carmen Balaña, Insitut Català d'Oncologia, Badalona, Spain
| |
Collapse
|
111
|
Lange SES, Liu J, Adkins DR, Powell MA, Van Tine BA, Mutch DG. Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center. Gynecol Oncol 2016; 140:307-12. [PMID: 26718726 PMCID: PMC4861068 DOI: 10.1016/j.ygyno.2015.12.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 12/16/2015] [Accepted: 12/18/2015] [Indexed: 11/18/2022]
Abstract
OBJECTIVE A retrospective chart review was performed to determine patient outcomes before and after partnership by gynecologic oncologists (GYN/ONC) with a sarcoma center (SC) for patients with recurrent unresectable/metastatic (RM) uterine leiomyosarcoma (uLMS). METHODS 58 RM patients, identified from medical records of uLMS patients cared for by either GYN/ONC service and/or the SC between 1/1/2000-4/1/2014, were audited for patient and tumor characteristics, outcomes, and clinical trials enrollments. RESULTS Of the 58 patients, 26 patients (48%) were treated by GYN/ONC alone and 32 were treated by a combination of GYN/ONC and SC (52%). Age, race, tumor size, grade, presence of lymphovascular invasion, cervical involvement, and FIGO stage at diagnosis were not statistically different between the two groups. There was a significant difference between the number of clinical trial enrollments (0.07 vs 0.84 trials/patient, p<0.001) and the number of chemotherapy regimens prescribed (2.67 vs 4.29/patient, p=0.03) by GYN/ONC vs SC; the latter was driven by the number of clinical trial enrollments by the SC. Sixty-nine percent of patients referred to the SC were enrolled in at least one clinical trial, while just 8% of patients in the GYN/ONC group were enrolled in at least one clinical trial, a difference that is significant (p<0.0001). CONCLUSIONS Referral of RM uLMS patients by GYN/ONC to a dedicated clinical trials-based SC resulted in an increase in the number of chemotherapy regimens prescribed and clinical trial enrollments. Partnership between GYN/ONC and a dedicated SC with access to clinical trials should be encouraged for all RM uLMS patients.
Collapse
Affiliation(s)
- S E S Lange
- Division of Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States.
| | - J Liu
- Division of Public Health Sciences, Washington University in St. Louis, St. Louis, MO 63110, United States
| | - D R Adkins
- Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States
| | - M A Powell
- Division of Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States
| | - B A Van Tine
- Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States
| | - D G Mutch
- Division of Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States
| |
Collapse
|
112
|
Ducoulombier A, Cousin S, Kotecki N, Penel N. Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials. Crit Rev Oncol Hematol 2016; 98:73-80. [DOI: 10.1016/j.critrevonc.2015.10.020] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Revised: 09/09/2015] [Accepted: 10/29/2015] [Indexed: 10/22/2022] Open
|
113
|
Momtahen S, Curtin J, Mittal K. Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma. J Clin Med Res 2016; 8:181-9. [PMID: 26858789 PMCID: PMC4737027 DOI: 10.14740/jocmr2419w] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2015] [Indexed: 01/12/2023] Open
Abstract
A variety of chemotherapeutic agents have been used for treating recurrent or advanced stage uterine leiomyosarcoma (ULMS). The response rates of these current agents are disappointing, with partial response rates varying from 0% to 33%, and complete response rates varying from 0% to 8%. Recent studies have documented many molecular changes in ULMSs. Prominent amongst these are gains of growth factors C-MYC, Bcl-2, K-ras, and Ki-67, and losses in tumor suppressors p16, p53, Rb1, ING2 and D14S267. Various techniques that have been used to target these molecules are presented. Targeting specific therapies at these underlying molecular changes could potentially yield better response rates with fewer side effects.
Collapse
Affiliation(s)
- Shabnam Momtahen
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College of Cornell University, New York, NY, USA
| | - John Curtin
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Langone Medical Center, New York University School of Medicine, New York, NY, USA
| | - Khush Mittal
- Department of Pathology, Langone Medical Center, New York University School of Medicine, New York, NY, USA
| |
Collapse
|
114
|
Cooney EJ, Borowsky M, Flynn C. Case report: Atypical, 'symplastic' leiomyoma recurring as leiomyosarcoma in the vagina. Gynecol Oncol Rep 2016; 14:4-5. [PMID: 26793761 PMCID: PMC4688827 DOI: 10.1016/j.gore.2015.07.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 07/21/2015] [Accepted: 07/30/2015] [Indexed: 11/30/2022] Open
Abstract
Leiomyosarcoma in the vagina is rare. Atypical fibroids recurring as leiomyosarcoma Leiomyomas should be classified based on recurrence risk.
Collapse
Affiliation(s)
- Elizabeth J Cooney
- Department of Obstetrics & Gynecology,Christiana Care Health System,Newark DE, USA
| | - Mark Borowsky
- Department of Obstetrics & Gynecology,Christiana Care Health System,Newark DE, USA
| | - Cynthia Flynn
- Department of Pathology,Christiana Care Health System,Newark DE, USA
| |
Collapse
|
115
|
Abstract
Uterine leiomyosarcoma (uLMS) is a rare mesenchymal tumor of the gynecologic tract. Although diagnosed in only 1-3% of patients with uterine cancer, uLMS accounts for the majority of uterine cancer-related deaths. The standard of care for patients with uLMS includes total hysterectomy and bilateral salpingo-oophorectomy (BSO). There are no standard recommendations regarding adjuvant or palliative therapy. Many cytotoxic and targeted agents have been studied in clinical trials in an effort to identify an effective therapy that may alter the natural history of this disease. Unfortunately, as of now, there are no adjuvant therapy regimens that improve overall survival in this patient population. There is, therefore, an unmet need to identify a novel therapy that will improve the survival of women diagnosed with this aggressive disease. Here we summarize the existing literature on adjuvant therapy in uLMS, specifically highlighting advances made in the last 5 years.
Collapse
Affiliation(s)
- Jennifer A Ducie
- a Gynecology Service, Department of Surgery , Memorial Sloan Kettering Cancer Center , New York , NY , USA
| | - Mario M Leitao
- a Gynecology Service, Department of Surgery , Memorial Sloan Kettering Cancer Center , New York , NY , USA
| |
Collapse
|
116
|
Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol 2015; 77:133-46. [PMID: 26563256 PMCID: PMC4706580 DOI: 10.1007/s00280-015-2809-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 06/12/2015] [Indexed: 01/24/2023]
Abstract
Soft tissue sarcomas (STS) constitute an uncommon and heterogeneous group of tumours, which require a complex and specialized multidisciplinary management. The diagnostic approach should include imaging studies and core needle biopsy performed prior to undertaking surgery. Wide excision is the mainstay of treatment for localized sarcoma, and associated preoperative or postoperative radiotherapy should be administered in high-risk patients. Adjuvant chemotherapy was associated with a modest improvement in survival in a meta-analysis and constitutes a standard option in selected patients with high-risk STS. In metastatic patients, surgery must be evaluated in selected cases. In the rest of patients, chemotherapy and, in some subtypes, targeted therapy often used in a sequential strategy constitutes the treatment of election. Despite important advances in the understanding of the pathophysiology of the disease, the advances achieved in therapeutic results may be deemed still insufficient. Moreover, due to the rarity and complexity of the disease, the results in clinical practice are not always optimal. For this reason, the Spanish Group for Research on Sarcoma (GEIS) has developed a multidisciplinary clinical practice guidelines document, with the aim of facilitating the diagnosis and treatment of these patients in Spain. In the document, each practical recommendation is accompanied by level of evidence and grade of recommendation on the basis of the available data.
Collapse
Affiliation(s)
| | | | | | - Silvia Bague
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | - Josefina Cruz
- Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain
| | | | | | | | | | - Ramona Verges
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Joan Viñals
- Hospital Universitario de Bellvitge, Barcelona, Spain
| | | |
Collapse
|
117
|
Sugarbaker P, Ihemelandu C, Bijelic L. Cytoreductive Surgery and HIPEC as a Treatment Option for Laparoscopic Resection of Uterine Leiomyosarcoma with Morcellation: Early Results. Ann Surg Oncol 2015; 23:1501-7. [PMID: 26545375 DOI: 10.1245/s10434-015-4960-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Indexed: 11/18/2022]
Abstract
BACKGROUND A new and frequently utilized treatment option for symptomatic uterine leiomyoma is laparoscopic resection with morcellation so the specimen can be extracted through a small abdominal incision or through the vagina. Some of these tumors (approximately 0.2 %) have malignant foci of uterine leiomyosarcoma (ULMS) that is widely disseminated in the process of resection. These patients are in need of effective additional treatments. METHODS Patients with ULMS were treated with a standardized cytoreductive surgery (CRS), hyperthermic perioperative chemotherapy (HIPEC), and early postoperative intraperitoneal chemotherapy (EPIC) specifically designed for sarcomatosis. Distribution of disease by Peritoneal Cancer Index was recorded by preoperative computed tomography or magnetic resonance imaging and at the time of CRS. Completeness of cytoreduction score was determined after completion of CRS. Morbidity and mortality, as well as interval to start systemic chemotherapy, were prospectively recorded. RESULTS Six patients with disseminated ULMS after morcellation or slicing underwent CRS and HIPEC plus EPIC. All six patients had complete visible clearing of sarcoma prior to perioperative chemotherapy. Early intervention after morcellation was associated with a lesser extent of disease. No serious morbidity or mortality was observed in early referral patients, and patients eligible for systemic chemotherapy were treated with perioperative chemotherapy within 6 weeks of the CRS. CONCLUSIONS The future use of laparoscopic resection of ULMS with morcellation is currently under debate. However, patients after laparoscopic resection and morcellation have CRS and HIPEC plus EPIC as a treatment option. Results regarding short-term benefit are suggested by these early data, especially with early referral.
Collapse
Affiliation(s)
- Paul Sugarbaker
- Center for Gastrointestinal Malignancies, MedStar Washington Cancer Institute, Washington, DC, USA.
| | - Chukwuemeka Ihemelandu
- Center for Gastrointestinal Malignancies, MedStar Washington Cancer Institute, Washington, DC, USA
| | - Lana Bijelic
- Surgical Oncology, Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA, USA
| |
Collapse
|
118
|
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Int J Gynecol Cancer 2015; 25:296-302. [PMID: 25581897 DOI: 10.1097/igc.0000000000000344] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
OBJECTIVE Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy characterized by a poor prognosis due to a high rate of local and metastatic recurrences. Chemotherapy with doxorubicin or ifosfamide or both is associated with a 10% to 30% objective response rate. We report a monocentric experience with doxorubicin, cisplatin, and ifosfamide (API) combination in the setting of multimodal treatment of advanced or metastatic ULMS. PATIENTS AND METHODS This monocentric retrospective study included patients with metastatic or locally advanced ULMS with a physiological age younger than 65 years treated in first line with a multimodal aggressive approach with API chemotherapy. Treatment consisted of doxorubicin 50 mg/m2 d1, ifosfamide 3 g/m2 per day d1d2 plus mesna, cisplatin 75 mg/m2 d3, plus G-CSF; every 3 weeks up to 6 cycles. Surgery, radiation therapy, or radiofrequency ablation therapy of metastatic sites was associated whenever possible. RESULTS Thirty-eight patients received API for metastatic or locally advanced ULMS. Median age was 51 years (40-64 years); 4 (11%) patients were treated for a locally advanced disease and 34 (89%) for metastatic disease. Sixteen patients responded (4 complete responses+12 partial responses) among 33 evaluable patients (objective response rate, 48%); 8 and 9 patients had, respectively, stable and progressive disease. Twelve patients had surgeries with 9 surgical complete responses and 3 surgical partial responses. Median progression-free and overall survival in the whole population were 9.8 and 27 months, respectively. Main grade 3-4 toxicities in 38 patients were neutropenia (74%), thrombocytopenia (60%), anemia (55%), fatigue (18%), and vomiting (13%). Febrile neutropenia was observed in 37% of patients. CONCLUSIONS Despite the toxicity observed, API is an effective treatment which compares favorably with other first-line therapies for patients with metastatic or advanced ULMS.
Collapse
|
119
|
Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review. Case Rep Urol 2015; 2015:198381. [PMID: 26351611 PMCID: PMC4550759 DOI: 10.1155/2015/198381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2015] [Revised: 07/28/2015] [Accepted: 07/29/2015] [Indexed: 11/21/2022] Open
Abstract
Prostate cancer is the most common cancer in men. Docetaxel is a common chemotherapeutic agent that has proven its efficacy in the treatment of patients with both castration sensitive and resistant metastatic prostate cancer. We report a case of acute respiratory distress syndrome (ARDS) in a patient with metastatic prostate cancer treated with docetaxel (Taxotere). ARDS is very rare but life threatening complication of docetaxel which requires aggressive supportive care and close monitoring. Better awareness and prompt diagnosis of this treatment related ARDS will improve the effectiveness and outcome of its management.
Collapse
|
120
|
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer 2015; 24:S61-6. [PMID: 25341583 DOI: 10.1097/igc.0000000000000261] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVES The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management. METHODS Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made. RESULTS The approach to management of uterine and ovarian leiomyosarcoma management is reviewed. CONCLUSIONS Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.
Collapse
|
121
|
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer 2015; 51:1794-802. [PMID: 26066736 DOI: 10.1016/j.ejca.2015.05.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 05/12/2015] [Accepted: 05/13/2015] [Indexed: 11/22/2022]
Abstract
BACKGROUND Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation. Gemcitabine and docetaxel (GD) has efficacy in metastatic STS and may be better tolerated. We conducted a study to compare toxicities and efficacies of these regimens. METHODS This open-label, phase II, single institution trial randomised 80 patients with localised, resectable, high grade STS ⩾ 5 cm to either neo/adjuvant AI or GD. AI was doxorubicin (75 mg/m(2)) and ifosfamide (2.5 g/m(2)/d) on days 1-3 with mesna 500 mg/m(2)/dose. GD was gemcitabine 900 mg/m(2) on days 1, 8 and docetaxel 100mg/m(2) day 8. Both arms included filgrastim. The primary end-point was hospitalisation rate. Secondary end-points included disease-free survival (DFS) and overall survival (OS). RESULTS Between November 2004 and August 2012, 80 evaluable patients were randomised, 37 to AI and 43 to GT. In the AI arm, 13/37 (35%) patients were hospitalised versus 11/43 (26%) in the GD arm (p=0.25). Hospitalisation rates were not significantly different after adjusting for age, gender, location, chemotherapy and number of cycles (p=0.17). The 2-year and median DFS in the AI arm were 57% and 37 months, respectively, and 74% and not yet reached, respectively, in the GD arm. The most common serious adverse events with AI were haematologic. Metabolic derangements and constitutional symptoms were most common with GD. CONCLUSIONS Hospitalisation rate was less with GD but not statistically significant. There was a trend towards longer DFS with GD, and the regimen was tolerable, suggesting GD merits further study.
Collapse
|
122
|
Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol Cancer 2015; 24:1434-40. [PMID: 25248114 DOI: 10.1097/igc.0000000000000221] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVES This study aimed to identify prognostic factors influencing the outcome of recurrent or persistent uterine leiomyosarcoma (ULMS). METHODS All patients with recurrent or persistent ULMS who underwent treatment at the participating institutions between January 2000 and December 2010 were identified from the tumor registry. The Kaplan-Meier method was used to generate overall survival data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model. RESULTS One hundred fifteen (68.8%) patients who had recurrent/persistent disease were identified, 40 (34.8%) had persistent disease, and 75 (65.2%) had a recurrence. Median follow-up time was 24.9 months. The 5-year postrelapse survival rate was 15% and was not significantly different between women with recurrent or persistent disease (16% vs 13%; P = 0.1). Variables identified affecting the 5-year postrelapse survival rate included low number of mitosis at the time of diagnosis (<25, 25% vs 5%; P = 0.002), time to relapse from original diagnosis (≤6 vs >6 months, 8% vs 22%; P = 0.003)), and surgical treatment (17% vs 12%; P = 0.01). Age, stage, chemotherapy at time of original diagnosis or at the time of relapse, site of recurrence, and single versus multiple sites of recurrence were not associated with survival. In a multivariate Cox regression model, only low number of mitosis (hazard ratio, 0.5; 95% confidence interval, 0.3-0.8, P = 0.02) was identified as a predictor of overall survival. CONCLUSIONS The prognosis of patients with recurrent/persistent ULMS is, in general, poor. Women who have low number of mitosis at the time of diagnosis seemed to have better postrelapse survival.
Collapse
|
123
|
Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. Sarcoma 2015; 2015:704124. [PMID: 26089739 PMCID: PMC4451518 DOI: 10.1155/2015/704124] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Accepted: 04/28/2015] [Indexed: 01/21/2023] Open
Abstract
The treatment of advanced uterine leiomyosarcomas (U-LMS) represents a considerable challenge. Radiological diagnosis prior to hysterectomy is difficult, with the diagnosis frequently made postoperatively. Whilst a total abdominal hysterectomy is the cornerstone of management of early disease, the role of routine adjuvant pelvic radiotherapy and adjuvant chemotherapy is less clear, since they may improve local tumor control in high risk patients but are not associated with an overall survival benefit. For recurrent or disseminated U-LMS, cytotoxic chemotherapy remains the mainstay of treatment. There have been few active chemotherapy drugs approved for advanced disease, although newer drugs such as trabectedin with its pleiotropic mechanism of actions represent an important addition to the standard front-line systemic therapy with doxorubicin and ifosfamide. In this review, we outline the therapeutic potential and in particular the emerging evidence-based strategy of therapy with trabectedin in patients with advanced U-LMS.
Collapse
|
124
|
Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res 2015; 5:13. [PMID: 25987978 PMCID: PMC4434867 DOI: 10.1186/s13569-015-0029-8] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Accepted: 05/05/2015] [Indexed: 11/22/2022] Open
Abstract
Background Gemcitabine and docetaxel have been shown to be active in pre-treated relapsed leiomyosarcoma. This study investigated the combination as first line treatment in patients with unresectable locally advanced/metastatic leiomyosarcoma. Methods Patients received gemcitabine 900 mg/m2 days 1 and 8, and docetaxel 100 mg/m2 day 8, administered 3-weekly for up to 8 cycles, with GCSF support on days 9–15. Patients who had received previous radiotherapy were treated at 75% dose. Patients were evaluated for response by RECIST 1.0 after cycles 2, 4, 6 and 8, and 3-monthly after completing treatment. Results Forty-four patients were evaluable for response. Eligible patients had histologically proven leiomyosarcoma of the uterus (54.5%) or other sites (45.5%). Thirty-nine patients (84.4%) had metastatic disease, and 5 (15.6%) had locally advanced disease. Six patients (13.6%) had grade 1 disease, and 23 (75%) had grade 2/3 disease. All patients had demonstrated disease progression prior to trial entry. Responses were as follows: partial response 11 (25.0%), stable disease (confirmed) 16 (36.6%), stable disease (unconfirmed) 7 (15.9%), progressive disease 10 (22.7%). Median progression-free survival and overall survival were 7.1 months (95% CI 5.7–8.3) and 17.9 months (95% CI 10.6–25.2), respectively. Progression free rates at 3 and 6 months were 70.5% (95% CI 56.7–84.2%) and 59.1% (95% CI 44.3–73.9%). Conclusions This study demonstrates gemcitabine and docetaxel to be active in locally advanced/metastatic leiomyosarcoma in the first line setting. Further investigation comparing with current standard therapies for leiomyosarcoma is warranted.
Collapse
Affiliation(s)
- Beatrice Seddon
- Sarcoma Unit, University College Hospital, 1st Floor Central, 250 Euston Road, London, NW1 2PG UK
| | - Michelle Scurr
- Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ UK
| | - Robin L Jones
- Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ UK
| | - Zoe Wood
- Sarcoma Unit, University College Hospital, 1st Floor Central, 250 Euston Road, London, NW1 2PG UK
| | | | - Cyril Fisher
- Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ UK
| | - Adrienne Flanagan
- Department of Histopathology, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP UK
| | - Jonanthan Sunkersing
- Sarcoma Unit, University College Hospital, 1st Floor Central, 250 Euston Road, London, NW1 2PG UK
| | - Roger A'Hern
- ICR Clinical Trials and Statistics Unit, Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG UK
| | - Jeremy Whelan
- Sarcoma Unit, University College Hospital, 1st Floor Central, 250 Euston Road, London, NW1 2PG UK
| | - Ian Judson
- Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ UK
| |
Collapse
|
125
|
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma 2015; 2015:532478. [PMID: 26074722 PMCID: PMC4446476 DOI: 10.1155/2015/532478] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 05/01/2015] [Indexed: 12/22/2022] Open
Abstract
Gemcitabine (G) and docetaxel (D) are commonly used to treat recurrent/metastatic soft tissue sarcoma. This study tested the hypothesis that outcomes would be improved by addition of bevacizumab (B).
The initial design was randomized double-blind trial of G + D + B versus G + D + placebo. Due to slow accrual this was modified to single-arm open-label G + D + B. Eligible patients had diagnosis of leiomyosarcoma, pleomorphic undifferentiated sarcoma, pleomorphic liposarcoma, or angiosarcoma. Treatment was B 15 mg/kg on d1, G 900 mg/m2 on d1 and d8, and D 75 mg/m2 on d8, q21d. Primary endpoint was progression-free survival (PFS) at 6 months and would be met if ≥17 patients were progression-free at 6 m. Secondary endpoints are response rate, PFS at 3 m, overall survival, and toxicity.
Of 44 patients enrolled, 35 were treated with GDB and evaluable for safety and efficacy. Median age was 55, 50% male, most ECOG 0. Toxicity is mostly myelosuppression with one deep vein thrombosis and one small bowel perforation possibly related to B. There were 17 partial responses (49%) by RECIST 1.1. Among 35 patients, the number who remained on study and progression-free was 24 at 3 m and 15 at 6 m. 9 withdrew prior to 6 m for reasons other than toxicity or progression. PFS at 6 m was 65% (95% CI: 51–85%).
The primary endpoint of 6 m PFS was not met due to censoring of patients who withdrew. However PFS at 3 m (76%) was promising and response rate was higher than expected from G + D.
Collapse
|
126
|
Sonnenblick A, Eleyan F, Peretz T, Ospovat I, Merimsky O, Sella T, Peylan-Ramu N, Katz D. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. Mol Clin Oncol 2015; 3:829-832. [PMID: 26171190 DOI: 10.3892/mco.2015.545] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Accepted: 02/20/2015] [Indexed: 11/06/2022] Open
Abstract
A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. Data were collected on all patients with advanced non-resectable STS who were treated with a fixed dose 700 mg/m2 gemcitabine in combination with 70 mg/m2 paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40-70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression-free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.
Collapse
Affiliation(s)
- Amir Sonnenblick
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Feras Eleyan
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Tamar Peretz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Inna Ospovat
- Department of Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel
| | - Ofer Merimsky
- Department of Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel
| | - Tamar Sella
- Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Nili Peylan-Ramu
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| | - Daniela Katz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
| |
Collapse
|
127
|
Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015; 16:457-64. [PMID: 25795402 DOI: 10.1016/s1470-2045(15)70070-7] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown activity in pretreated leiomyosarcoma. We did a single-group, multicentre, phase 2 trial (LMS-02) to assess the effect of first-line doxorubicin and trabectedin combination on disease control and survival. METHODS Adults (18 years to physiological age ≤70 years) with measurable metastatic or unresectable uterine leiomyosarcoma or soft-tissue leiomyosarcoma who had not received any previous chemotherapy were enrolled at 19 centres in France. Treatment consisted of 60 mg/m(2) intravenous doxorubicin followed by 1·1 mg/m(2) trabectedin in a 3 h intravenous infusion on day 1, both by the central venous route, and 6 mg subcutaneous pegfilgrastim on day 2, repeated every 3 weeks for up to six cycles. Surgery for residual disease was permitted. The primary endpoint was the proportion of patients achieving disease control, defined as complete or partial response or stable disease. Stratification was done by anatomical site and analyses were per protocol. This study is registered with ClinicalTrials.gov, number NCT02131480. FINDINGS Between July 28, 2010, and May 10, 2013, 109 patients were enrolled and treated, of whom 108 were assessable for response: 47 in the uterine leiomyosarcoma group and 61 in the soft-tissue leiomyosarcoma group. 32 (68%) patients in the uterine leiomyosarcoma group and 45 (74%) in the soft-tissue leiomyosarcoma group received all six cycles of treatment. Of 47 patients with uterine leiomyosarcoma, 28 (59·6%, 95% CI 44·3-73·6) achieved a partial response and 13 (27·7%, 15·6-42·6) stable disease; 41 (87·2%, 74·3-95·2) patients achieved disease control. Of 61 patients with soft-tissue leiomyosarcoma, two (3·3%, 95% CI 0·4-11·7) achieved a complete response, 22 (36·1%, 25·0-50·8) had a partial response, and 32 (52·5%, 40·8-67·3) had stable disease; 56 (91·8%, 81·9-97·3) of patients achieved disease control. The most common grade 3-4 treatment-associated adverse events were neutropenia (84 [78%] of 108 patients), increased alanine aminotransferase concentration (42 [39%]), thrombocytopenia (40 [37%]), anaemia (29 [27%]), febrile neutropenia (26 [24%]), and fatigue (21 [19%]). INTERPRETATION Despite expected but manageable toxic effects, these results support the activity of doxorubicin plus trabectedin as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma. This combination should be developed further in a phase 3 trial against the present standard of care. FUNDING Pharmamar and Amgen.
Collapse
Affiliation(s)
- Patricia Pautier
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
| | - Anne Floquet
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - Christine Chevreau
- Department of Medical Oncology, Institut Claudius-Regaud, Toulouse, France
| | - Nicolas Penel
- Department of Medical Oncology, Centre Oscar-Lambret, Lille, France
| | - Cécile Guillemet
- Department of Medical Oncology, Centre Henri-Becquerel, Rouen, France
| | - Corinne Delcambre
- Department of Medical Oncology, Centre François-Baclesse, Caen, France
| | - Didier Cupissol
- Department of Medical Oncology, Centre Val d'Aurelle, Montpellier, France
| | - Frédéric Selle
- Department of Medical Oncology, Hôpital Tenon, Paris, France
| | - Nicolas Isambert
- Department of Medical Oncology, Centre GF Leclerc, Dijon, France
| | | | - Antoine Thyss
- Department of Medical Oncology Centre Antoine Lacassagne, Nice, France
| | - François Bertucci
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Emmanuelle Bompas
- Department of Medical Oncology, Centre René Gauducheau, Saint Herblain, France
| | | | - Olivier Collard
- Department of Medical Oncology, Institut de Cancérologie de la Loire, Saint Priest en Jarez, France
| | - Sandrine Lavau-Denes
- Department of Medical Oncology, Centre Hospitalo-Universitaire Dupuytren, Limoges, France
| | - Patrick Soulié
- Department of Medical Oncology, Centre Paul Papin, Angers, France
| | - Maud Toulmonde
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - Axel Le Cesne
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - Benjamin Lacas
- Department of Biostatistics, Institut Gustave Roussy, Villejuif, France
| | - Florence Duffaud
- Department of Medical Oncology, La Timone University Hospital, Marseille, France
| | | |
Collapse
|
128
|
Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015; 33:1180-5. [PMID: 25713428 DOI: 10.1200/jco.2014.58.3781] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
PURPOSE Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients with uterine leiomyosarcoma (uLMS). This study aimed to determine whether the addition of bevacizumab to gemcitabine-docetaxel increases progression-free survival (PFS) in uLMS. PATIENTS AND METHODS In this phase III, double-blind, placebo-controlled trial, patients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-docetaxel plus bevacizumab or gemcitabine-docetaxel plus placebo. PFS, overall survival (OS), and objective response rates (ORRs) were compared to determine superiority. Target accrual was 130 patients to detect an increase in median PFS from 4 months (gemcitabine-docetaxel plus placebo) to 6.7 months (gemcitabine-docetaxel plus bevacizumab). Treatment effects on PFS and OS were described by hazard ratios (HRs), median times to event, and 95% CIs. RESULTS In all, 107 patients were accrued: gemcitabine-docetaxel plus placebo (n = 54) and gemcitabine-docetaxel plus bevacizumab (n = 53). Accrual was stopped early for futility. No statistically significant differences in grade 3 to 4 toxicities were observed. Median PFS was 6.2 months for gemcitabine-docetaxel plus placebo versus 4.2 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.12; P = .58). Median OS was 26.9 months for gemcitabine-docetaxel plus placebo and 23.3 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.07; P = .81). Objective responses were observed in 17 (31.5%) of 54 patients randomly assigned to gemcitabine-docetaxel plus placebo and 19 (35.8%) of 53 patients randomly assigned to gemcitabine-docetaxel plus bevacizumab. Mean duration of response was 8.6 months for gemcitabine-docetaxel plus placebo versus 8.8 months for gemcitabine-docetaxel plus bevacizumab. CONCLUSION The addition of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improve PFS, OS, or ORR. Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.
Collapse
Affiliation(s)
- Martee L Hensley
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN.
| | - Austin Miller
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| | - David M O'Malley
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| | - Robert S Mannel
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| | - Kian Behbakht
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| | - Jamie N Bakkum-Gamez
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| | - Helen Michael
- Martee L. Hensley, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York; Austin Miller, NRG Oncology, Buffalo, NY; David M. O'Malley, The Ohio State University, Columbus, OH; Robert S. Mannel, University of Oklahoma, Oklahoma City, OK; Kian Behbakht, University of Colorado Denver, Aurora, CO; Jamie N. Bakkum-Gamez, Mayo Clinic, Rochester, MN; and Helen Michael, Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
129
|
Abstract
PURPOSE OF REVIEW The purpose of this article is to review current evidence-based management strategies for patients with recurrent and metastatic uterine leiomyosarcoma (LMS). We will focus on treatment of advanced multifocal disease as well as new developments in targeted cancer therapies. RECENT FINDINGS The management of patients with advanced uterine LMS is divided between those with localized and those with disseminated disease. Selected patients with localized or single-organ oligometastatic disease may benefit from surgical resection. For patients with disseminated disease, fixed-dose-rate gemcitabine plus docetaxel is an appropriate first-line chemotherapy regimen. Other active cytotoxic agents include doxorubicin, ifosfamide, and dacarbazine. The role of trabectedin (approved by the European Medicine Agency to be marketed for advanced or metastatic soft tissue sarcoma) is being explored. Trials are also underway for targeted therapy in uterine LMS. Currently, the only approved targeted therapy for advanced soft tissue sarcoma is pazopanib. In patients with small volume and slowly progressive estrogen receptor/progesterone receptor-positive disease, antiestrogen therapy with an aromatase inhibitor is a reasonable alternative to observation alone. SUMMARY Despite recent advances, overall survival for advanced disease remains poor and identification of novel agents with activity in LMS is clearly needed.
Collapse
|
130
|
Uterine myxoid leiomyosarcoma with tumor embolism extending into the right atrium. Case Rep Obstet Gynecol 2015; 2015:316262. [PMID: 25722901 PMCID: PMC4333190 DOI: 10.1155/2015/316262] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 01/22/2015] [Accepted: 01/22/2015] [Indexed: 12/26/2022] Open
Abstract
Uterine myxoid leiomyosarcoma (MLMS) is an extremely rare variant of uterine leiomyosarcoma; only 56 cases were reported from 1982 to 2013. Uterine MLMS is characterized by a myxoid appearance and highly malignant behavior. We herein report a case involving a 65-year-old woman with uterine MLMS with a large tumor embolism that reached the right atrium. A total abdominal hysterectomy, bilateral salpingooophorectomy, and tumor embolism resection with the use of a heart-lung machine were performed. Epirubicin-ifosfamide chemotherapy in the adjuvant setting led to reductions in both the tumor emboli and peritoneal dissemination. The patient retained a good quality of life for 10 months after the initial surgery. She then developed progressive disease despite treatment with pazopanib. She died of her disease 14 months after the initial surgery. Although complete surgical resection of the tumor is desirable, tumor reduction surgery followed by adjuvant chemotherapy might help to retain a good quality of life. This is the first reported case of a primary uterine MLMS with tumor emboli.
Collapse
|
131
|
Liebner DA. The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J Surg Oncol 2015; 111:622-31. [DOI: 10.1002/jso.23866] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 11/13/2014] [Indexed: 01/13/2023]
Affiliation(s)
- David A. Liebner
- Department of Internal Medicine; Division of Medical Oncology; The Ohio State University; Columbus Ohio
- Department of Biomedical Informatics; Division of Computational Biology and Bioinformatics; The Ohio State University; Columbus Ohio
| |
Collapse
|
132
|
Ward KK, McHale MT. Uterine Corpus Cancers. Gynecol Oncol 2015. [DOI: 10.1007/978-1-4939-1976-5_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
133
|
Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma. BMC Cancer 2014; 14:981. [PMID: 25523155 PMCID: PMC4320583 DOI: 10.1186/1471-2407-14-981] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2014] [Accepted: 12/09/2014] [Indexed: 12/13/2022] Open
Abstract
Background Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. Methods Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. Results Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS, respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in terms of OS (p < 0.0001). Conclusion At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological tumor behavior.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Stephan Polterauer
- Department of Gynecology and Gynecologic Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, 1090 Vienna, Austria.
| |
Collapse
|
134
|
Abstract
INTRODUCTION Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials on medical treatment of uterine LMS were collected and critically analyzed. Other study types were secondarily considered when pertinent. AREAS COVERED Doxorubicin (DOX), ifosfamide and dacarbazine have been long used in the treatment of this malignancy. Novel active agents are represented by gemcitabine, docetaxel, trabectedin, pazopanib and aromatase inhibitors, whereas the role of eribulin, bevacizumab, aflibercept and mammalian target of rapamycin inhibitors is still investigational. EXPERT OPINION DOX alone, gemcitabine alone, DOX + dacarbazine and gemcitabine + docetaxel may be treatment options for first-line and second-line therapies. However, the clinical benefit of the combination chemotherapy versus single-agent chemotherapy is still debated. Trabectedin is a promising agent for recurrent uterine LMS, able to obtain a prolonged disease control, with 3-month and 6-month progression-free survival rates exceeding 50 and 30%, respectively, and with sometimes unexpectedly durable responses. Pazopanib is the only approved targeted therapy. Hormone therapy with aromatase inhibitors may be a therapeutic option in heavily treated patients with slowly progressive, steroid receptor-positive tumors. Whenever possible, women with recurrent uterine LMS should be encouraged to enter well-designed clinical trials aimed to detect novel active agents.
Collapse
Affiliation(s)
- Angiolo Gadducci
- University of Pisa, Division of Gynecology and Obstetrics, Department of Experimental and Clinical Medicine , Via Roma 56, Pisa, 56127 , Italy +39 50 992609 ; +39 50 992354 ;
| | | |
Collapse
|
135
|
Colombo C, Baratti D, Kusamura S, Deraco M, Gronchi A. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. J Surg Oncol 2014; 111:570-9. [PMID: 25351775 DOI: 10.1002/jso.23808] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 08/13/2014] [Indexed: 01/28/2023]
Abstract
Locally advanced sarcomas in the extremity and in the retroperitoneum/abdominal cavity (peritoneal sarcomatosis, PS) can be managed administering chemotherapy locally using isolated limb perfusion (ILP) and hyperthermic intraperitoneal chemotherapy (HIPEC), respectively. In this review, the authors discuss the pros and cons of the use of these locoregional therapies in locally advanced soft tissue sarcoma, with a view to establishing their role in the multidisciplinary approach to these difficult diseases.
Collapse
Affiliation(s)
- Chiara Colombo
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | | | | | | | | |
Collapse
|
136
|
High-Grade Undifferentiated Sarcomas of the Uterus: Diagnosis, Outcomes, and New Treatment Approaches. Curr Oncol Rep 2014; 16:405. [DOI: 10.1007/s11912-014-0405-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
137
|
Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014; 135:44-8. [PMID: 25091619 DOI: 10.1016/j.ygyno.2014.07.101] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Revised: 07/21/2014] [Accepted: 07/28/2014] [Indexed: 12/24/2022]
Abstract
OBJECTIVE The combination of gemcitabine and docetaxel is the standard first-line therapy for recurrent or metastatic uterine leiomyosarcoma. There is no standard second-line therapy. Ixabepilone is a semi-synthetic analog of epothilone B that binds to the same site on beta tubulin as paclitaxel and may be a more potent polymerizer of tubulin. We sought to determine the activity of ixabepilone as a single agent as second-line treatment for patients with metastatic uterine leiomyosarcoma who had received taxane based therapy. METHODS Eligible women with unresectable uterine leiomyosarcoma progressing after prior cytotoxic therapy containing a taxane were treated with ixabepilone 40 mg/m(2) on day one of a 21 day cycle. Patients with prior pelvic radiation were treated without dose reduction. Response Evaluation Criteria in Solid Tumors (RECIST) response was assessed by computed tomography (CT). RESULTS Twenty-three of 26 women were evaluable (two wrong histology, one never treated) with two of 23 receiving 1 cycle of therapy. There were no complete or partial responses. Stable disease (SD) was seen in four patients (17.4%, median 3.4 months). Seventeen patients (73.9%) had increasing disease (PD) and two patients were inevaluable per RECIST. One patient had SD over 6 cycles of treatment. Median PFS for all 23 patients was 1.4 months and overall survival was 7.0 months. The predominant grade 3 or 4 toxicity was uncomplicated myelosuppression: neutropenia grade 3 (13%), grade 4 (17%), and anemia grade 3 (22%). CONCLUSION Ixabepilone as a single agent is not an active second-line therapy for uterine leiomyosarcoma previously treated with a taxane.
Collapse
Affiliation(s)
- Linda R Duska
- University of Virginia Health Systems, Division of Gynecology Oncology, P.O. Box 800712, Charlottesville, VA 22908, USA.
| | - John A Blessing
- Gynecologic Oncology Group, Statistical & Data Center, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
| | - Jacob Rotmensch
- Rush-Presbyterian St. Luke's Medical Center, 1725 W. Harrison, Suite 842 Professional Bldg., Chicago, IL 60612, USA.
| | - Robert S Mannel
- The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA.
| | - Parviz Hanjani
- Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, 1 Widener, 1200 Old York Road, Abington, PA 19001, USA.
| | - Peter G Rose
- Cleveland Clinic, 9500 Euclid Ave./A81, Cleveland, OH 44195, USA.
| | - Don S Dizon
- Massachusetts General Hospital, GYN Oncology, 55 Fruit St., Yawkey 9E, Boston, MA 02114, USA.
| |
Collapse
|
138
|
Blay JY. Going further in the knowledge of Yondelis®; what's new in clinical trials? Future Oncol 2014; 10:s7-s12. [PMID: 25048046 DOI: 10.2217/fon.14.114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Trabectedin is indicated for the treatment of advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines and ifosfamide, or as first-line therapy for patients who are unsuited to receive these agents. Since trabectedin first became available for clinical investigation in 1995, numerous retrospective analyses and Phase II studies have documented its activity and provided useful insights into its unique clinical profile. An extensive research program of randomized studies was subsequently undertaken to identify methods of optimizing the use of trabectedin in clinical practice. Some main areas of interest involved its use in the first-line setting, its use in combination regimens and its activity in specific sarcoma subtypes. In this article, clinical trial results are reviewed with the aim of continually refining trabectedin's place in the therapy of advanced STS.
Collapse
Affiliation(s)
- Jean-Yves Blay
- Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008 Lyon, France.
| |
Collapse
|
139
|
Pink D, Richter S, Gerdes S, Andreou D, Tunn PU, Busemann C, Ehninger G, Reichardt P, Schuler MK. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. Oncology 2014; 87:95-103. [PMID: 25011671 DOI: 10.1159/000362602] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2014] [Accepted: 03/31/2014] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. METHODS A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. RESULTS Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. CONCLUSIONS In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.
Collapse
Affiliation(s)
- Daniel Pink
- Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
140
|
Thanopoulou E, Thway K, Khabra K, Judson I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res 2014; 4:5. [PMID: 25018868 PMCID: PMC4094538 DOI: 10.1186/2045-3329-4-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Accepted: 06/13/2014] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Aromatase inhibitors (AIs) have not been used consistently as part of the management of hormone receptor positive uterine leiomyosarcomas (ULMS). As a result, the published data regarding the efficacy of AIs in this subtype of ULMS are sparse. METHODS We performed a retrospective electronic medical record review of patients with ULMS treated with an AI, in the 1st or the 2nd line setting, at the Sarcoma Unit of the Royal Marsden Hospital between 2001 and 2012. We assessed progression-free survival (PFS), objective response and toxicities and explored the correlation of the intensity of the hormone receptor status, as well as of the grade with PFS. RESULTS Sixteen patients with measurable advanced ULMS were treated with an AI in our unit. All of them were oestrogen receptor (ER) and progesterone receptor (PgR) positive. Letrozole was used in all patients as 1st line endocrine therapy, while exemestane was mainly prescribed as 2nd line (83%). Median PFS in 1st line was 14 months (95% CI: 0 - 30 months), and prolonged PFS was more likely to be observed in patients with low grade compared to high grade ULMS (20 months vs. 11 months), and in moderately/strongly ER positive compared to weakly ER positive ULMS (20 months vs. 12 months). Best response was partial response (PR) in 2/16 patients (12.5%) and clinical benefit (CB), defined as complete response (CR) + PR + stable disease ≥6 months, was observed in 10/16 patients (CB rate (CBR) 62.5%). Median duration of 2nd line was 3 months and median PFS was not reached. The 1-year progression-free rate for the 2nd line AI was 80%. Best response was PR in one patient and CBR was 50%. AIs were well tolerated in both lines of treatment. CONCLUSIONS In this population of patients with hormone positive ULMS, AIs achieved a significant CBR (62.5%) in 1st line, which was retained in 2nd line (CBR: 50%). The relatively prolonged median PFS (14 months), along with the favourable toxicity profile could place AIs among the first choices of systemic treatment in hormone positive ULMS, preferably in strongly positive (>90%), and/ or low grade and low volume disease.
Collapse
Affiliation(s)
- Eirini Thanopoulou
- Sarcoma Unit, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK
| | - Khin Thway
- Sarcoma Unit, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK
| | - Komel Khabra
- Sarcoma Unit, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK
| | - Ian Judson
- Sarcoma Unit, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK
| |
Collapse
|
141
|
Mach CM, Urh A, Anderson ML. Bowel perforation associated with temsirolimus use in a recently irradiated patient. Am J Health Syst Pharm 2014; 71:919-23. [DOI: 10.2146/ajhp130145] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Claire M. Mach
- College of Pharmacy, University of Houston, and Division of Gynecologic Oncology, Baylor College of Medicine, Houston, TX
| | - Anze Urh
- Division of Gynecologic Oncology, Baylor College of Medicine
| | - Matthew L. Anderson
- Division of Gynecologic Oncology and Dan L. Duncan Cancer Center, Baylor College of Medicine
| |
Collapse
|
142
|
Adjuvant chemotherapy in stage I–II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients. Gynecol Oncol 2014; 133:531-6. [DOI: 10.1016/j.ygyno.2014.03.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2014] [Revised: 02/25/2014] [Accepted: 03/01/2014] [Indexed: 01/21/2023]
|
143
|
Abstract
Uterine leiomyosarcomas are rare but challenging tumours. They occur most commonly around or shortly after the menopause. Their clinical behaviour is very variable, from highly aggressive to very indolent. Most are diagnosed unexpectedly and thus initially operated on by general gynaecologists. This article discusses the important surgical issues and the role of adjuvant treatments such as radiotherapy and chemotherapy. Important new international trials are opening to address these issues. Relapsed disease is usually incurable, but a subgroup of patients may benefit from repeated surgical procedures, hormones and ablative therapies. The choice of drugs for chemotherapy is discussed. New approaches with targeted agents have yet to establish themselves in treatment of leiomyosarcomas.
Collapse
Affiliation(s)
- Nicholas Reed
- Beatson Oncology Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, G12 0YN, UK,
| |
Collapse
|
144
|
Yamagami W, Susumu N, Ninomiya T, Kuwahata M, Takigawa A, Nomura H, Kataoka F, Tominaga E, Banno K, Tsuda H, Aoki D. A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma. Mol Clin Oncol 2014; 2:591-595. [PMID: 24940501 DOI: 10.3892/mco.2014.272] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Accepted: 03/20/2014] [Indexed: 11/06/2022] Open
Abstract
There is currently insufficient evidence to recommend a specific chemotherapeutic regimen as standard treatment for uterine sarcomas. In this study, we investigated the toxicity and effectiveness of ifosfamide, adriamycin and cisplatin (IAP therapy) in patients with progressive and recurrent uterine sarcoma. A total of 11 patients with progressive or recurrent uterine sarcoma containing leiomyosarcoma (LMS), undifferentiated endometrial sarcoma (UES) or adenosarcoma, who were diagnosed at our institution, were retrospectively investigated. We recorded the adverse events, response rate and progression-free survival in these cases. The histological types included LMS (54.5%), adenosarcoma (27.3%) and UES (18.2%). Grade ≥3 leukopenia or neutropenia were observed in all the cases, febrile neutropenia developed in 45.5% of the patients and grade 4 thrombocytopenia developed in 3 cases (27.3%). With IAP therapy, the response rate was 36.4% and the disease control rate was 90.9%. Therefore, IAP therapy may be a viable option as chemotherapy for uterine sarcoma.
Collapse
Affiliation(s)
- Wataru Yamagami
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Nobuyuki Susumu
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Tomomi Ninomiya
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Michiko Kuwahata
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Aya Takigawa
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Hiroyuki Nomura
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Fumio Kataoka
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Eiichiro Tominaga
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Kouji Banno
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Hiroshi Tsuda
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| | - Daisuke Aoki
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan
| |
Collapse
|
145
|
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15:415-23. [PMID: 24618336 DOI: 10.1016/s1470-2045(14)70063-4] [Citation(s) in RCA: 761] [Impact Index Per Article: 76.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone. METHODS We did this phase 3 randomised controlled trial (EORTC 62012) at 38 hospitals in ten countries. We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18-60 years with a WHO performance status of 0 or 1. They were randomly assigned (1:1) by the minimisation method to either doxorubicin (75 mg/m(2) by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/m(2); 25 mg/m(2) per day, days 1-3) plus ifosfamide (10 g/m(2) over 4 days with mesna and pegfilgrastim) as first-line treatment. Randomisation was stratified by centre, performance status (0 vs 1), age (<50 vs ≥50 years), presence of liver metastases, and histopathological grade (2 vs 3). Patients were treated every 3 weeks till progression or unacceptable toxic effects for up to six cycles. The primary endpoint was overall survival in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00061984. FINDINGS Between April 30, 2003, and May 25, 2010, 228 patients were randomly assigned to receive doxorubicin and 227 to receive doxorubicin and ifosfamide. Median follow-up was 56 months (IQR 31-77) in the doxorubicin only group and 59 months (36-72) in the combination group. There was no significant difference in overall survival between groups (median overall survival 12·8 months [95·5% CI 10·5-14·3] in the doxorubicin group vs 14·3 months [12·5-16·5] in the doxorubicin and ifosfamide group; hazard ratio [HR] 0·83 [95·5% CI 0·67-1·03]; stratified log-rank test p=0·076). Median progression-free survival was significantly higher for the doxorubicin and ifosfamide group (7·4 months [95% CI 6·6-8·3]) than for the doxorubicin group (4·6 months [2·9-5·6]; HR 0·74 [95% CI 0·60-0·90], stratified log-rank test p=0·003). More patients in the doxorubicin and ifosfamide group than in the doxorubicin group had an overall response (60 [26%] of 227 patients vs 31 [14%] of 228; p<0·0006). The most common grade 3 and 4 toxic effects-which were all more common with doxorubicin and ifosfamide than with doxorubicin alone-were leucopenia (97 [43%] of 224 patients vs 40 [18%] of 223 patients), neutropenia (93 [42%] vs 83 [37%]), febrile neutropenia (103 (46%) vs 30 [13%]), anaemia (78 [35%] vs 10 [5%]), and thrombocytopenia (75 [33%]) vs one [<1%]). INTERPRETATION Our results do not support the use of intensified doxorubicin and ifosfamide for palliation of advanced soft-tissue sarcoma unless the specific goal is tumour shrinkage. These findings should help individualise the care of patients with this disease. FUNDING Cancer Research UK, EORTC Charitable Trust, UK NHS, Canadian Cancer Society Research Institute, Amgen.
Collapse
|
146
|
Payne MJ, Macpherson RE, Bradley KM, Hassan AB. Trabectedin in Advanced High-Grade Uterine Leiomyosarcoma: A Case Report Illustrating the Value of (18)FDG-PET-CT in Assessing Treatment Response. Case Rep Oncol 2014; 7:132-8. [PMID: 24707261 PMCID: PMC3975749 DOI: 10.1159/000355224] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
We report the case of a 60-year-old woman with metastatic high-grade uterine leiomyosarcoma who achieved a delayed response to second-line therapy with the marine-derived drug trabectedin (Yondelis(®), PharmaMar). We used 2-deoxy-2-[(18)F] fluorodeoxyglucose (FDG)-positron emission tomography (PET-CT) imaging as a tool for response monitoring in parallel with conventional re-staging according to Response Evaluation Criteria in Solid Tumours (RECIST) using computed tomography (CT). We illustrate the role of serial (18)FDG-PET-CT imaging in the functional assessment of tumour response. Three cycles after commencement of trabectedin treatment, a reduction of the maximum standardized uptake value (SUVmax) of the solid component of the pelvic mass was observed, indicating a cystic or necrotic response in the tumour to trabectedin. After 7 cycles of treatment, on (18)FDG-PET-CT there was clear evidence of ongoing disease improvement: the solid pelvic components were at worst stable, with an unchanged SUVmax, and possibly marginally reduced in size, while the pulmonary metastases had further reduced in size and become FDG negative; the bony metastases were stable. After a total of 13 cycles of treatment, administered over 13 months, the patient showed signs of progression on an (18)FDG-PET-CT scan. The safety profile of trabectedin remained manageable, showing no evidence of cumulative toxicity and being associated with a preserved quality of life. This report illustrates potential limitations of RECIST in response assessments and the critical role of serial (18)FDG-PET-CT imaging in assessing response to trabectedin treatment. Therefore, we propose that (18)FDG-PET-CT may improve the assessment of response to trabectedin in selected patients.
Collapse
Affiliation(s)
- M J Payne
- Department of Medical Oncology, Oxford Cancer and Haematology Centre, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK
| | - R E Macpherson
- Department of Radiology and Nuclear Medicine, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK
| | - K M Bradley
- Department of Radiology and Nuclear Medicine, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK
| | - A B Hassan
- Department of Medical Oncology, Oxford Cancer and Haematology Centre, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK
| |
Collapse
|
147
|
Abstract
Uterine fibroids are a major cause of morbidity in women of a reproductive age (and sometimes even after menopause). There are several factors that are attributed to underlie the development and incidence of these common tumors, but this further corroborates their relatively unknown etiology. The most likely presentation of fibroids is by their effect on the woman's menstrual cycle or pelvic pressure symptoms. Leiomyosarcoma is a very rare entity that should be suspected in postmenopausal women with fibroid growth (and no concurrent hormone replacement therapy). The gold standard diagnostic modality for uterine fibroids appears to be gray-scale ultrasonography, with magnetic resonance imaging being a close second option in complex clinical circumstances. The management of uterine fibroids can be approached medically, surgically, and even by minimal access techniques. The recent introduction of selective progesterone receptor modulators (SPRMs) and aromatase inhibitors has added more armamentarium to the medical options of treatment. Uterine artery embolization (UAE) has now been well-recognized as a uterine-sparing (fertility-preserving) method of treating fibroids. More recently, the introduction of ultrasound waves (MRgFUS) or radiofrequency (VizAblate™ and Acessa™) for uterine fibroid ablation has added to the options of minimal access treatment. More definite surgery in the form of myomectomy or hysterectomy can be performed via the minimal access or open route methods. Our article seeks to review the already established information on uterine fibroids with added emphasis on contemporary knowledge.
Collapse
Affiliation(s)
- Aamir T Khan
- Birmingham Women’s Hospital, Edgbaston, Birmingham, UK
| | | | - Janesh K Gupta
- Academic Department of Obstetrics and Gynaecology, University of Birmingham, Birmingham, UK
| |
Collapse
|
148
|
Schmitt T, Kasper B. New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. Expert Rev Anticancer Ther 2014; 9:1159-67. [PMID: 19671035 DOI: 10.1586/era.09.64] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Thomas Schmitt
- University of Heidelberg, Department of Internal Medicine V, Germany
| | | |
Collapse
|
149
|
Radons J. The role of inflammation in sarcoma. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 816:259-313. [PMID: 24818727 DOI: 10.1007/978-3-0348-0837-8_11] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Sarcomas encompass a heterogenous group of tumors with diverse pathologically and clinically overlapping features. It is a rarely curable disease, and their management requires a multidisciplinary team approach. Chronic inflammation has emerged as one of the hallmarks of tumors including sarcomas. Classical inflammation-associated sarcomas comprise the inflammatory malignant fibrous histiocytoma and Kaposi sarcoma. The identification of specific chromosomal translocations and important intracellular signaling pathways such as Ras/Raf/MAPK, insulin-like growth factor, PI3K/AKT/mTOR, sonic hedgehog and Notch together with the increasing knowledge of angiogenesis has led to development of targeted therapies that aim to interrupt these pathways. Innovative agents like oncolytic viruses opened the way to design new therapeutic options with encouraging findings. Preclinical evidence also highlights the therapeutic potential of anti-inflammatory nutraceuticals as they can inhibit multiple pathways while being less toxic. This chapter gives an overview of actual therapeutic standards, newest evidence-based studies and exciting options for targeted therapies in sarcomas.
Collapse
Affiliation(s)
- Jürgen Radons
- Department of Radiotherapy and Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany,
| |
Collapse
|
150
|
Ricci S, Giuntoli RL, Eisenhauer E, Lopez MA, Krill L, Tanner EJ, Gehrig PA, Havrilesky LJ, Secord AA, Levinson K, Frasure H, Celano P, Fader AN. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol 2013; 131:629-33. [DOI: 10.1016/j.ygyno.2013.08.037] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 08/27/2013] [Accepted: 08/30/2013] [Indexed: 10/26/2022]
|